NervGen Doses First Patient in Phase 3 RESTORE SCI Trial
NervGen dosed the first participant in RESTORE, a Phase 3 registrational study of NVG-291 in chronic cervical motor-incomplete spinal cord injury. Enrollment is expected to complete in H2 2027, with topline data expected in H1 2028.